Continuing Medical Education (CME) Programs
The Asthma and Allergy Foundation of America (AAFA), in collaboration with Medlive, offers a variety of free continuing medical education (CME) programs for health care providers. The programs aim to help health care providers learn more about asthma, allergies, atopic diseases, and treatment options. They also provide resources for patient and caregiver support.
During the programs, expert panelists cover a wide range of topics. For upcoming programs, you can join live or watch on demand later. You can find CME programs on:
- Asthma
- Atopic dermatitis (AD) and eczema
- Eosinophilic esophagitis (EoE)
- Food allergy
- Nasal polyps
- Type 2 inflammation
- Urticaria
Sign up for our monthly newsletters and stay updated on upcoming or on-demand programs.
AAFA offers asthma management education for nurses and respiratory therapists through our Asthma Management Education Online (AME-O) course. Learn more about our AME-O course and how to earn 9.75 contact hours.
Upcoming programs
There are no upcoming programs at this time. Be sure to check back soon.
Programs on Asthma and Allergy
View our programs on asthma and allergy below. Some programs offer continuing medical education credits (AMA PRA Category 1 Credit™), as noted below.
Asthma
On-demand CME
Guideline-driven Management of Moderate and Severe Asthma to Reduce Emergency Care Needs for Exacerbations: A Team-based Initiative
Topics covered during this program include:
- Proactive management to reduce asthma exacerbations
- Case-based learning to improve clinical decision-making and biologic treatment selection
- Best practices for ER-to-clinic care transition and patient retention
Earn AMA PRA Category 1 Credit™ through May 15, 2026. Watch on demand.
On-demand Learning
Applying Guidelines and Latest Evidence to the Management of Moderate‐to‐Severe Asthma in Children and Adults
Topics discussed during this program include:
- The impact of moderate-to-severe asthma on airway remodeling and lung development in children
- Conditions that occur frequently with asthma
- Strategies to develop personalized asthma treatment plans
Please note AMA PRA Category 1 Credit™ is no longer available.
Applying the Latest Guidelines and Recommendations to Initiate Biologic Therapy and Control Moderate-to-Severe Asthma Symptoms
Topics discussed during this program include:
- The burden of uncontrolled asthma
- The impact of asthma phenotypes/endotypes and type 2 comorbidities
- Current data on the efficacy and safety of biologics
Please note the AMA PRA Category 1 Credit™ is no longer available.
Biologic Therapy for Patients with Severe Asthma: Impeding the Inflammatory Cascade
Topics discussed during this program include:
- Roles of various inflammatory pathways in severe asthma
- Mechanisms of action of various therapies and their safety and efficacy data
- How a new treatment option targeting TSLP can be integrated into asthma management plan
Please note AMA PRA Category 1 Credit™ is no longer available.
TARGETING ASTHMA: Community-based Strategies to Enhance Care Access for Children, Adolescents, and Adults – Focus on Social Determinants of Health and Inequities of Care
Topics discussed during this program include:
- Strategies to enhance access to individualized care among people of racial and ethnic minorities
- How to identify patients with moderate-to-severe asthma who may benefit from targeted biologic agents
- How to identify the place of type-2-targeted biologics in the management of moderate-to-severe asthma
Please note AMA PRA Category 1 Credit™ is no longer available.
Food Allergy
On-demand Learning
At the Forefront of Food Allergies: Preventive Strategies to Improve Outcomes
Topics discussed during this program include:
- The changing landscape of food allergy management
- Newer approaches to enhance food allergen tolerance
- The key roles of patients and their families when making therapeutic decisions
Please note AMA PRA Category 1 Credit™ is no longer available. There are two sessions in this program.
Session 1
Session 2
Programs on Allergic Conditions
View our programs on allergic conditions such as chronic spontaneous urticaria (CSU), eosinophilic esophagitis (EoE), atopic dermatitis (AD), and more. You can earn an AMA PRA Category 1 Credit™, as noted.
Atopic Dermatitis
On-demand CME
Uncovering the Spectrum of Comorbidities in Moderate-to-Severe Atopic Dermatitis: How to Navigate the Nuances to Comprehensive Care
Topics covered during this program include:
- Comorbid conditions common with atopic dermatitis (AD)
- The impact of comorbid conditions on AD management
- Strategies to improve overall treatment and quality of life
Earn AMA PRA Category 1 Credit™ through October 6, 2026. Watch on demand.
On-demand Learning
Atopic Dermatitis and Its Comorbid Conditions: How Knowing About Them Will Help Guide Your Treatment Decisions
Topics covered during this program include:
- Current evidence for currently approved agents for the treatment of moderate-to-severe atopic dermatitis (AD)
- How the presence of comorbidities can influence the treatment of moderate-to-severe AD
- How to help patients reach long-term control of their disease
Please note AMA PRA Category 1 Credit™ is no longer available.
Disparity and Equity in Moderate-to-Severe AD Care: Enhancing Access to Multidisciplinary Care for Patients from Diverse Populations
Topics covered during this program include:
- The impacts that age, race, and ethnicity have on atopic dermatitis (AD)
- Management of moderate-to-severe atopic dermatitis
- The unique challenges that people from diverse racial and ethnic group face when attempting to access care
Please note AMA PRA Category 1 Credit™ is no longer available.
Endophenotypes, Evidence, and Long-Term Outcomes in Moderate-to-Severe Atopic Dermatitis Management: A Decision Library
Topics covered during this program include:
- Alignment of therapeutic decisions to clinical endophenotypes in patients of different age groups and races
- Evidence-based treatment recommendations to achieve long-term disease control
- Strategies to encourage shared-decision-making with patients
Please note AMA PRA Category 1 Credit™ is no longer available. There are four modules in this program.
Module 1
Module 2
Module 3
Module 4
Eosinophilic Esophagitis
On-demand Learning
Enhancing Diagnosis and Access to Treatment in EoE: What You Need to Know from Your Patients
Topics discussed during this program include:
- Guidance on EoE diagnosis
- The Importance of asking questions to uncover adaptive behaviors
- Details of the current treatment paradigm
Please note AMA PRA Category 1 Credit™ is no longer available.
Eosinophilic Esophagitis: Guidelines and Emerging Evidence for Effective Management Strategies
Topics discussed during this program include:
- How to recognize the symptoms of eosinophilic esophagitis (EoE) across a variety of patient ages to facilitate an early diagnosis
- Emerging data on new, more efficient, targeted agents for the management of EoE
Please note AMA PRA Category 1 Credit™ is no longer available.
Nasal Polyps
On-demand CME
Smell Matters: Breakthrough Strategies to Restore Olfaction in CRSwNP
Topics covered during this program include:
- Strategies to restore sense of smell
- When and how to use biologic therapies to treat chronic rhinosinusitis with nasal polyps (CRSwNP)
- How to personalize treatment plans to improve patient outcomes
Earn AMA PRA Category 1 Credit™ through Nov. 17, 2026. Watch on demand.
On-demand Learning
Caring for Patients with Nasal Polyps in 2023: When to Consider a Biologic or Surgery?
Topics covered during this program include:
- The latest understanding of chronic rhinosinusitis with nasal polyps (CRSwNP), or nasal polyps
- People at high risk for recurrence of nasal polyps
- Treatment options for people with nasal polyps
Please note AMA PRA Category 1 Credit™ is no longer available. There are four modules in this program.
Module 1
Module 2
Module 3
Module 4
Cases in Practice: Applying Proposed Care Pathways for Interdisciplinary Collaboration to the Management of Nasal Polyps
Topics covered during this program include:
- Cases illustrating the adoption of biologics as a therapeutic option for nasal polyps
- The underlying pathophysiology of nasal polyps driven by type 2 inflammation
- Strategies for implementing interdisciplinary collaborative care
Please note AMA PRA Category 1 Credit™ is no longer available.
Diagnostic Workup of the Patient with Uncontrolled Severe Nasal Polyps: Proposed Pathway to Determine Candidacy for Biologic Therapy
Topics covered during this program include:
- Patient factors to predict relapse risk and determine candidacy for biologics
- Emerging models for interdisciplinary collaboration in the care of people with nasal polyps
Please note AMA PRA Category 1 Credit™ is no longer available.
Moving Toward a Targeted Approach for Nasal Polyps
Topics discussed during this course include:
- The patient burden of nasal polyps
- Limitations of traditional nasal polyp treatments and emerging therapies for those with nasal polyps
- Rationale for targeted approaches to nasal polyp management
Please note AMA PRA Category 1 Credit™ is no longer available.
Multidisciplinary Approach to the Management of CRS with Refractory Nasal Polyps: ENT, Allergist, and Patient Partnerships to Enhance Care and QoL
Topics discussed during this program include:
- Patient-centered treatment options for chronic rhinosinusitis with nasal polyps (CRSwNP)
- Disease burden
- The impacts that biologics and surgery have on symptoms and quality of life (QoL)
Please note AMA PRA Category 1 Credit™ is no longer available.
Surgery or Biologic for Nasal Polyps? A Close Look at the Evidence
Topics discussed during this program include:
- The underlying pathways that lead to nasal polyps and drive recurrent disease and treatment resistance
- The burdens faced by patients with nasal polyps
- Evidence supporting the efficacy and safety of biologic agents for the treatment of nasal polyps
Please note AMA PRA Category 1 Credit™ is no longer available.
Type 2 Inflammation
On-demand CME
Multidisciplinary Management of T2 Inflammatory Diseases: Case-based Discussion
Topics covered during this program include:
- The impact of coexisting type 2 inflammatory diseases on severity and treatment
- Strategies to implement multidisciplinary management models
- Data evaluation for targeted biologics
Earn AMA PRA Category 1 Credit™ through August 20, 2026. Watch on demand.
Targeting T2 Inflammation: Taking Action to Efficiently Manage Complex Patients – A Multidisciplinary Panel Discussion
Topics covered during this program include:
- The exploration of the overlapping nature of type 2 inflammatory conditions like asthma, atopic dermatitis, EoE, and CRSwNP
- How eosinophilic inflammation impacts disease severity and treatment
- Current and emerging biologic therapies that are changing the future of T2 care
Earn AMA PRA Category 1 Credit™ through June 12, 2026. Watch on demand.
Urticaria
On-demand CME
“Hive Hopes” for Chronic Spontaneous Urticaria: Targeting Key Immune Pathways with the Latest Emerging Therapies
Topics covered during this program include:
- Updated international guidelines and key diagnostic tools
- The role of inflammatory pathways
- How delays in diagnosis can leave patients without relief
Earn AMA PRA Category 1 Credit™ through July 28, 2026. Watch on demand.
On-demand Learning
The Increasing Importance of Identifying Urticaria Subtypes to Achieve Control: Opportunities with T2 Inflammation Targeting Agents
Topics discussed during this program include:
- The relationships between chronic inducible urticaria (CIndU) triggers and underlying pathophysiologic pathways
- How to optimize treatment of chronic spontaneous urticaria (CSU) and CIndU
- Strategies to identify urticaria subtypes
Please note AMA PRA Category 1 Credit™ is no longer available.
Chronic Spontaneous Urticaria: New Hope with Emerging Targeted Agents
Topics discussed during this program include:
- The latest in chronic spontaneous urticaria (CSU) treatment options
- Management and treatment escalation standards
- Perspectives from the patient journey
Please note AMA PRA Category 1 Credit™ is no longer available.
